USP 621 Revisions - S/N Calculation, Sensitivity and Peak Symmetry
Waters Corporation: Solving Problems That Matter - a Waters webinar series featuring USP speakers
Solving Problems That Matter - a Waters webinar series featuring USP speakers
Episode 2: USP 621 Revisions - S/N Calculation, Sensitivity and Peak Symmetry
Summary
USP General Chapter <621> "Chromatography" was recently updated to harmonize with other pharmacopeias. With this harmonization there are changes to how some of the system suitability calculations are done in Waters™ Empower™ Software, including Resolution, Plate Number and Signal-to-Noise.
Key Learning Objective: Learn about the changes in the harmonized USP<621> and how to address the new calculations in Empower CDS.
Who Should Attend: Scientists and lab managers applying USP<621> to system suitability calculations.
Presenter: Neil Lander (Principal Product Manager, Waters Corporation)
Neil has worked for Waters Corporation since 1994 and has held a variety of positions including Technical Support Specialist, Technical Trainer, Manager Customer Education and currently, Principal Marketing Manager focusing on Informatics solutions. He provides internal support for Empower Chromatography Data System and is focused on developing laboratory software solutions that help organizations achieve their scientific and operational objectives. Prior to joining Waters, he was an analytical chemist where he gained experience in both the cosmetics and specialty chemical industries.
Moderated by: Isabelle Vu Trieu (Pharmaceutical Market Development Manager, Americas, Waters Corporation)
Isabelle is a business development professional dedicated to delivering benefits to analytical scientists in the life sciences industry. With over 20 years of experience in providing chromatography and mass spectrometry solutions, Isabelle is particularly interested in helping pharmaceutical scientists achieve the data quality and integrity needed to drive decisions for drug quality, safety and efficacy. Isabelle joined Waters in 2009 and currently manages the development of the pharmaceutical market in the Americas. She holds Masters’ degrees in Chemistry from Columbia University and the University Claude Bernard in Lyon, France as well as a Chemical Engineering degree from Ecole Supérieure de Chimie Physique Electronique in Lyon, France.